Mirum Pharmaceuticals Appoints Rob Myers, M.D. as Chief Medical Officer to Lead Global Medical and Clinical Development
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a rare disease-focused pharmaceutical company developing medicines for patients with serious and often underserved conditions, has announced the appointment of Rob Myers, M.D., as its new Chief Medical Officer. Dr. Myers will officially assume the role on September 21, 2026, joining Mirum’s senior leadership team at an important stage in the company’s continued growth and portfolio expansion.
In his new position, Dr. Myers will oversee Mirum’s global medical and clinical development organizations. His responsibilities will include helping guide the company’s clinical development strategy and advancing its pipeline of potential therapies as Mirum works to expand treatment options for people living with rare diseases.
The appointment brings an experienced physician-scientist and drug development executive to Mirum. Dr. Myers has more than 20 years of experience in medicine, clinical research and pharmaceutical development, with a particular focus on liver diseases and hepatology. His background includes leadership roles spanning industry and academia, as well as extensive involvement in clinical programs designed to address significant unmet medical needs.
Experienced Physician-Scientist Joins Mirum Leadership Team
Dr. Myers is widely recognized for his expertise in hepatology and has developed a substantial scientific and clinical research record throughout his career. His work includes more than 200 peer-reviewed publications, reflecting extensive contributions to the understanding and treatment of liver diseases.
A significant portion of his development experience has focused on primary sclerosing cholangitis (PSC), a chronic liver disease characterized by inflammation and damage to the bile ducts. His work in this area has included contributions to understanding the natural history of PSC, as well as its diagnosis and management.
His expertise, however, extends beyond PSC and hepatology. More recently, Dr. Myers has worked on programs involving metabolism and endocrine-related disorders, providing him with experience across a broader range of therapeutic areas.
For Mirum, this combination of deep liver-disease knowledge and broad clinical development experience is expected to support the company as it advances its existing portfolio while preparing for further growth.
Leadership Experience Across Industry and Drug Development
Before joining Mirum, Dr. Myers served as Chief Medical Officer and Head of Development at OrsoBio. In that role, he was responsible for senior-level development leadership, bringing together his medical and clinical expertise with strategic drug development experience.
Earlier in his career, Dr. Myers held senior leadership positions at Gilead Sciences. During his time at the company, he oversaw clinical development programs involving several areas of significant interest within liver and gastrointestinal medicine.
His responsibilities included programs focused on liver fibrosis, cholestatic liver diseases and gastrointestinal inflammation. These roles provided experience in managing complex clinical development programs and advancing investigational medicines through various stages of development.
His background in both academia and the pharmaceutical industry has also allowed him to approach drug development from multiple perspectives. His scientific research has contributed to the broader understanding of liver disease, while his industry leadership has involved translating scientific insights into clinical development strategies.
That combination is particularly relevant to Mirum, whose development efforts are centered on rare diseases in which clinical research can face challenges such as limited patient populations and significant unmet medical needs.
Appointment Comes at an Important Stage for Mirum
Mirum said Dr. Myers is joining at a significant point in the company’s evolution. The company expects continued growth in its commercial portfolio while also advancing an increasingly diverse late-stage pipeline.
As Mirum expands, leadership of its medical and clinical development functions will become increasingly important. The company is seeking to balance the responsibilities associated with an expanding commercial organization with the need to continue progressing potential new therapies through clinical development.
Chris Peetz, Chief Executive Officer of Mirum Pharmaceuticals, highlighted Dr. Myers’ experience as a strong fit for the company’s current portfolio and future direction.
Peetz described Myers as a proven development leader whose expertise aligns closely with Mirum’s objectives. He also emphasized the value of Myers’ deep understanding of liver disease alongside his broader experience leading clinical development activities.
According to Peetz, the appointment comes as Mirum prepares for expected commercial portfolio growth and manages a late-stage pipeline that is becoming increasingly diverse. He added that Dr. Myers will have an important role in helping the company advance potential breakthrough medicines for people affected by rare diseases.
Deep Expertise in Hepatology
Dr. Myers’ longstanding focus on hepatology is particularly relevant to Mirum’s development strategy.
Throughout his career, he has worked extensively on liver disease research, with particular contributions related to PSC. His scientific work has helped advance understanding of how PSC develops and progresses, as well as how the disease can be diagnosed and managed.
Primary sclerosing cholangitis remains a challenging area of medicine, and research into its natural history and clinical management is important for developing more effective therapeutic approaches.
Dr. Myers’ experience in this field gives him a detailed understanding of the scientific and clinical considerations involved in developing therapies for complex liver disorders.
His broader hepatology experience also encompasses liver fibrosis and cholestatic liver diseases, areas in which he gained clinical development leadership experience during his time at Gilead Sciences.
This background provides a foundation for contributing to development strategies involving liver-related diseases while also supporting Mirum’s efforts in other therapeutic areas.
Broadening Experience Beyond Liver Disease
Although hepatology has been a major focus of Dr. Myers’ career, his recent experience demonstrates a broader development perspective.
His work at OrsoBio included programs associated with metabolism and endocrine-related disorders. This exposure has expanded his experience beyond traditional liver-focused development and adds another dimension to his capabilities as Mirum continues to diversify its pipeline.
Modern rare disease drug development frequently requires multidisciplinary approaches, combining disease biology, clinical research, regulatory strategy and patient-focused development. Dr. Myers’ experience across different therapeutic areas may therefore help Mirum manage increasingly complex development programs.
His appointment also reflects the company’s emphasis on building leadership capabilities that can support both current medicines and future pipeline candidates.
Strong Academic and Medical Training
Dr. Myers has an extensive academic and clinical training background that complements his pharmaceutical industry experience.
He earned his medical degree and completed Internal Medicine training at Western University. He subsequently completed a Gastroenterology fellowship at the University of Calgary, followed by a Hepatology fellowship at Université de Paris VI.
In addition to his medical training, Dr. Myers earned a master’s degree in Epidemiology from the University of Calgary.
His training in epidemiology provides additional expertise relevant to clinical research and the analysis of disease patterns and outcomes. Combined with his specialization in gastroenterology and hepatology, this academic background has supported his work as both a physician-scientist and drug development leader.
The breadth of his training has enabled him to work at the intersection of patient care, clinical research and pharmaceutical development.
Focus on Advancing Medicines for Rare Diseases
In commenting on his appointment, Dr. Myers expressed enthusiasm about joining Mirum at an important stage of the company’s development.
He said Mirum has established a distinctive rare disease company by combining drug development and delivery expertise with a focus on conditions in which patients have historically had limited treatment options.
Dr. Myers said he is excited to work with the Mirum team as the company continues to grow and advances a pipeline of medicines that could potentially make a meaningful difference for patients and their families.
His comments reflect the broader objective of rare disease drug development: addressing conditions for which existing therapeutic options may be insufficient and where new medicines could provide significant benefits to patients.
With his experience in clinical development and his specialized knowledge of liver disease, Dr. Myers is expected to contribute to the company’s efforts to move potential therapies forward through clinical research and development.
Transition in Mirum’s Medical Leadership
Alongside the appointment of Dr. Myers, Mirum announced that Joanne Quan, M.D., will be departing the company.
Mirum expressed its appreciation to Dr. Quan for her leadership and contributions during her time with the organization. The company credited her with helping advance Mirum’s medicines for patients living with rare diseases.
The transition marks a change in medical leadership as Mirum prepares for the next phase of its development. While Dr. Quan departs, Dr. Myers will take responsibility for the company’s global medical and clinical development functions beginning September 21, 2026.
The leadership transition comes as Mirum seeks to build on its progress and manage an expanding portfolio of medicines and late-stage clinical programs.
Supporting Mirum’s Next Phase of Growth
The appointment of Rob Myers represents an effort by Mirum Pharmaceuticals to strengthen its medical and clinical development leadership as the company moves into its next phase of growth.
His more than two decades of experience in drug development, combined with a strong scientific record and specialized expertise in hepatology, gives him experience across both academic research and pharmaceutical development.
His background includes extensive work in PSC and other liver diseases, clinical development leadership at Gilead Sciences, executive responsibilities at OrsoBio, and recent experience in metabolic and endocrine-related disorders.
As Chief Medical Officer, Dr. Myers will lead Mirum’s global medical and clinical development functions and help guide the advancement of the company’s pipeline. His appointment is expected to be particularly important as Mirum manages anticipated commercial growth while progressing an increasingly diverse group of late-stage development programs.
For patients and families affected by rare diseases, the ultimate significance of the leadership change will depend on the company’s ability to translate its scientific and clinical programs into effective new treatment options. With Dr. Myers bringing extensive development expertise and a longstanding focus on complex diseases, Mirum is positioning its medical organization to support that objective as the company continues to advance its rare disease portfolio.
About Mirum Pharmaceuticals
Mirum Pharmaceuticals (NASDAQ: MIRM) is a leading rare disease company with a global footprint of approved products and a broad pipeline of investigational medicines. Purpose-built to bring forward breakthrough medicines for people with overlooked conditions, Mirum focuses on rare liver and rare genetic diseases, where it has built deep expertise and strong connections to patient communities. The company’s commercial portfolio includes LIVMARLI® (maralixibat) for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), CHOLBAM® (cholic acid) for bile-acid synthesis disorders, and CTEXLI® (chenodiol) for cerebrotendinous xanthomatosis (CTX).
Mirum’s clinical-stage pipeline includes volixibat, an IBAT inhibitor in late-stage development for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), brelovitug, a fully human monoclonal antibody in late-stage development for chronic hepatitis delta virus (HDV), zilurgisertib, an ALK2 inhibitor under regulatory review with the FDA for fibrodysplasia ossificans progressiva (FOP), and MRM-3379, a PDE4D inhibitor being evaluated for Fragile X syndrome (FXS).
Mirum’s success is driven by a team dedicated to advancing high impact medicines through strategic development, disciplined execution and purposeful collaboration across the rare disease ecosystem.